Trials / Unknown
UnknownNCT00100087
Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System
A Safety and Feasibility Study of the TheraSight(TM) Ocular Brachytherapy System for Treatment of Age-Related Macular Degeneration
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- Theragenics Corporation · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The study will investigate the safety and feasibility of using the TheraSight(TM) Brachytherapy System for treatment of wet age-related macular degeneration (AMD).
Detailed description
This is a multi-center randomized study of three doses of radiation (assigned 1:1:1) delivered by the TheraSight(TM) Brachytherapy System in participants with choroidal neovascularization (CNV) secondary to wet (exudative) AMD. Each participant receives a single dose of radiation delivered by one-time only brachytherapy. Participants are followed for three years after the radiation treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Ocular Brachytherapy |
Timeline
- Start date
- 2004-10-01
- First posted
- 2004-12-23
- Last updated
- 2005-06-24
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00100087. Inclusion in this directory is not an endorsement.